Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

(NASDAQ: ALT) has recently reported positive topline results from the IMPACT phase 2b trial of pemvidutide in the treatment ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...